Date post: | 11-Jan-2017 |
Category: |
Healthcare |
Upload: | industry-standard-research |
View: | 109 times |
Download: | 0 times |
BIOPROCESSING MARKET TRENDS AND OUTSOURCING DYNAMICS: 2016-2021A P R I L , 2 0 1 6
P R E V I E W O F
REPORT OVERVIEW
HOW YOU CAN USE THIS REPORT
D A T A C O L L E C T I O N I N Q 1 , 2 0 1 6
3 0 - M I N U T E W E B - B A S E D
S U R V E Y
79 PAGES
75 CHARTS
AND GRAPHS
VALUABLE FOR
MAJOR SECTIONS:1. Bioprocessing Market
Dynamics
2. Service Provider Perceptions and Selection
3. Trends, Predictions and Preferences
4. Study Data
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Full table of contents included on next page.
DRUG DEVELOPERS• Gain insight into where the biologics industry is heading over
the next five years with respect to protein expression systems utilized and types of biologics in development
• Understand the CMO usage patterns of industry peers to identify whether additional outsourcing advatanges can be obtained for your organization
• Learn the criteria used by peers to select bioprocessing contract manufacturers that help to scientifically and strategically evaluate service providers for bioprocessing projects
CONTRACT MANUFACTURERS• Pinpoint which CMO attributes have led to successful
outsourcing relationships, those that have caused service providers to lose bids and what truly drives sponsor satisfaction, then internally assess your company on these metrics
• Identify changes in demand for outsourced activities and services in order to prepare for future needs
• Better position your company to win business by understanding the dynamics of different buyer groups (by sponsor company type and geography) and developing targeted marketing to speak directly to their unique needs
PHARMA/BIOTECH
OUTSOURCING
CMO MARKETING
BUSINESS DEVELOPMENT
EXECUTIVE MANAGEMENT
OPERATIONS
Manufacturing biologics is a much more involved and
complicated process than the chemical synthesis required
for small molecule drugs. As a result, some sponsors are
unlikely to outsource the process because of its complexity.
Others are more likely to outsource bioprocessing because
they need access to scientific expertise not possessed in-
house.
ISR’s Bioprocessing Market Trends and Outsourcing
Dynamics: 2016-2021 report affords readers the opportunity
to gain insight into the bioprocessing market and where it’s
heading. This report provides an overview of the current
market dynamics for bioprocessing as well as an outlook
on what our survey respondents predict the marketplace
will look like in five years. The report also explores the
types of biologics sponsor organizations currently have
in development and on the market and the likelihood of
outsourcing a bioprocessing project by the type of biologic.
1 0 0 R E S P O N D E N T S F R O M N O R T H
A M E R I C A , E U R O P E , A N D A S I A
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
STUDY FINDINGS
10www.ISRreports.com ©2016 Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021
Bioprocessing Project & CMO VolumeThe average number of bioprocessing projects per year skews high at 14�4 due to the substantial proportion of respondents from large biopharma companies, where an average of 20�4 bioprocessing projects per year are conducted� More than half of all bioprocessing projects are outsourced, and an average of 5�7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs�
Large biopharma companies use an average of 7�1 CMOs, more than twice as many as non-large companies require to meet their outsourced bioprocessing needs (3�1)� Non-large biopharma outsources a much higher proportion of their bioprocessing than large biopharma (74% vs 48%), which relates back to non-large biopharmaceutical companies using CMOs for all of their manufacturing needs�
Respondents who work for biopharmaceutical companies headquartered in Europe averaged more bioprocessing projects per year than their North American counterparts� While outsourcing rates are similar (54% Europe vs 58% North America), European biopharmas require fewer CMOs on average (4�2 vs 6�5)�
“About how many bioprocessing projects (both in-house and outsourced) would you estimate your company conducts on average per year?” (Base=100)
“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)
“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)
4.2
6.5
3.1
7.1
5.7
54%
58%
74%
48%
57%
18.2
13.0
3.3
20.4
14.4
0 10 20 30 40 50 60 70 80
Western Europe (n=31)
North America (n=67)
Non-large Biopharma - R&D <$1B (N=36)
Large Biopharma - R&D $1B+ (n=64)
Overall (n=100)
# of Projects / % Outsourced / # of CMOs
Average # of Projects
% Outsourced
Average # of CMOs
© Industry Standard Research
S A M P L E P A G E :
BIOPROCESSING PROJECT & CMO VOLUMEISR surveyed 100 respondents at pharma and biotech companies. The Bioprocessing Market Dynamics section of this report includes data regarding current outsourcing volume, types of biologics outsourced, and predictions for future trends in the market.
This page details the average number of bioprocessing projects at each company, the percentage of these projects that are outsourced, and the average number of CMOs each company works with on bioprocessing projects.
Full data is available in the report.
C L O S E R L O O K
Understanding project volume and the degree to which bioprocessing is outsourced helps both drug developers and CMOs make strategic decisions.
Learn more in the full report:
www.ISRreports.com
STUDY FINDINGS
10www.ISRreports.com ©2016 Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021
Bioprocessing Project & CMO VolumeThe average number of bioprocessing projects per year skews high at 14�4 due to the substantial proportion of respondents from large biopharma companies, where an average of 20�4 bioprocessing projects per year are conducted� More than half of all bioprocessing projects are outsourced, and an average of 5�7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs�
Large biopharma companies use an average of 7�1 CMOs, more than twice as many as non-large companies require to meet their outsourced bioprocessing needs (3�1)� Non-large biopharma outsources a much higher proportion of their bioprocessing than large biopharma (74% vs 48%), which relates back to non-large biopharmaceutical companies using CMOs for all of their manufacturing needs�
Respondents who work for biopharmaceutical companies headquartered in Europe averaged more bioprocessing projects per year than their North American counterparts� While outsourcing rates are similar (54% Europe vs 58% North America), European biopharmas require fewer CMOs on average (4�2 vs 6�5)�
“About how many bioprocessing projects (both in-house and outsourced) would you estimate your company conducts on average per year?” (Base=100)
“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)
“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)
4.2
6.5
3.1
7.1
5.7
54%
58%
74%
48%
57%
18.2
13.0
3.3
20.4
14.4
0 10 20 30 40 50 60 70 80
Western Europe (n=31)
North America (n=67)
Non-large Biopharma - R&D <$1B (N=36)
Large Biopharma - R&D $1B+ (n=64)
Overall (n=100)
# of Projects / % Outsourced / # of CMOs
Average # of Projects
% Outsourced
Average # of CMOs
© Industry Standard Research
The average number of bioprocessing projects per year skews high at 14.4 due to the substantial proportion of respondents from large biopharma companies, where an average of 20.4 bioprocessing projects per year are conducted. More than half of all bioprocessing projects are outsourced, and an average of 5.7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs.
“About how many bioprocessing projects (both in-house and outsourced) would you estimate your company conducts on average per year?” (Base=100)
“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)
“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)
D A T A I N F U L L R E P O R T
D A T A I N F U L L R E P O R T
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports.
ABOUT INDUSTRY STANDARD RESEARCH
>> R E G I S T E R N O W>>Receive $250 instant credit towards any ISR report
>>Earn 10% credit towards all future purchases
>>Receive advanced notifications on ISR’s latest reports and free resources
SAVE ON THIS, OR ANY ISR REPORT, BY CREATING A FREE ACCOUNT
MORE INFORMATION
To get more information about this report, including the full table of contents, sample pages, and pricing, please download the full preview from ISR’s website:
https://www.isrreports.com/reports/bioprocessing-market-trends-and-outsourcing-dynamics-2016-2021/
TO LEARN MORE: CONTACT US AT [email protected] OR +1(919)301-0106
Biosimilars & Biologics
Clinical Trial Recruitment &
Retention
Commercialization Department Models & Structures
Trends & Technologies
Manufacturing Service Provider Quality Benchmarking
CUSTOM RESEARCH
UNDERSTAND YOUR MARKETSLeverage ISR’s experience and institutional knowledge to create a fit-for-purpose market research project that addresses the business decisions you need to make.
Are you:• Developing a new product or service?• Evaluating a new market?• Targeting a new customer segment?• Entering a new geography?• Needing a deeper understanding of your
customer or potential customer base?
UNDERSTAND YOUR CUSTOMERSWho makes the decisions and in what contexts? ISR can help you gain a deeper understanding of your customers’ decision-making units (DMUs) and decision-making processes (DMPs).
Key Questions Addressed:• What motivates the purchase decision?• How are companies, products, solutions, and/or
brands evaluated?• What factors drive the final buying decision?• Where are your customers won or lost in the
purchasing process?• Why were specific opportunities won or lost?• How do you keep customers engaged and
manage their loyalty over time?
CUSTOM RESEARCH SERVICES• Investigator Forum• Brand, Advertising, and Message Testing• Loyalty Management• New Product and Service Development• Competitive Intelligence• Strategy War Games• MORE
S O M E T H I N G T O C O N S I D E R
DISTINCTIVE – Receive novel insights from industry decision-makers on topics including: service provider quality, patient recruitment, biosimilars, clinical technology, manufacturing, clinical operations, and commercial activities.
UNRESTRICTED – ISR doesn’t sell seats. Instantly obtain access for all employees within your organization
AFFORDABLE – Receive access to ALL reports in ISR’s library, as well as those released during your subscription period. ISR’s competitive library pricing equates to the cost of a few individual report purchases.
LIBRARY ACCESS SUBSCRIPTIONISR’s library access subscription provides your entire organization access to our full library of syndicated market research reports (100+ titles) plus access to all reports (~25 per year) released during your subscription period. Our research categories include:
THE ISR DIFFERENCE
Mostly primary research; always appropriate for the topic
One size fits all; usually publically available data
To learn more, visit www.ISRreports.com
ISR’S REPORTS
THECOMMON
SYNDICATEDREPORT
VS.
RESEARCH METHODS
ISR’s proprietary data tools and channelssupport fast, high quality data collection
Struggle to recurit the right targets and enough of them
DATA COLLECTION
Sophisticated screening ensures genuine decision-makers make up respondents
Undisclosed methodologies and respondent demographics
RESPONDENTS
Robust sample sizes that instill confidence
Often insucient industry representationthat leaves you defending results
SAMPLE SIZE
Decades of experience means more insights that are immediately usable
Junior analysts capable of reporting numbers
ANALYSTS
ISR’S HEALTH PANELThe industry’s fastest growing panel of health care and pharmaceutical
professionals, with nearly 1,500 members worldwide.
BYJOB
LEVEL
Director 46%
Manager 29%
C-level 13%
VP 10%
BYEXPERIENCE
IN YEARS
16-20 years 23%
11-15 years 24%
6-10 years 11%
3-5 years 5%
20+ years 37%
BYCOMPANY
TYPE
Other 6%
Sponsor 78%
CRO 6%
ResearchSite 10%